{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:30:09Z","timestamp":1790839809323,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T00:00:00Z","timestamp":1547164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T00:00:00Z","timestamp":1547164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Dysregulation of RNA splicing by spliceosome mutations or in cancer genes is increasingly recognized as a hallmark of cancer. Small molecule splicing modulators have been introduced into clinical trials to treat solid tumors or leukemia bearing recurrent spliceosome mutations. Nevertheless, further investigation of the molecular mechanisms that may enlighten therapeutic strategies for splicing modulators is highly desired. Here, using unbiased functional approaches, we report that the sensitivity to splicing modulation of the anti-apoptotic\n                    <jats:italic>BCL2<\/jats:italic>\n                    family genes is a key mechanism underlying preferential cytotoxicity induced by the SF3b-targeting splicing modulator E7107. While\n                    <jats:italic>BCL2A1<\/jats:italic>\n                    ,\n                    <jats:italic>BCL2L2<\/jats:italic>\n                    and\n                    <jats:italic>MCL1<\/jats:italic>\n                    are prone to splicing perturbation,\n                    <jats:italic>BCL2L1<\/jats:italic>\n                    exhibits resistance to E7107-induced splicing modulation. Consequently, E7107 selectively induces apoptosis in BCL2A1-dependent melanoma cells and MCL1-dependent NSCLC cells. Furthermore, combination of BCLxL (\n                    <jats:italic>BCL2L1<\/jats:italic>\n                    -encoded) inhibitors and E7107 remarkably enhances cytotoxicity in cancer cells. These findings inform mechanism-based approaches to the future clinical development of splicing modulators in cancer treatment.\n                  <\/jats:p>","DOI":"10.1038\/s41467-018-08150-5","type":"journal-article","created":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T18:10:07Z","timestamp":1546884607000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators"],"prefix":"10.1038","volume":"10","author":[{"given":"Daniel","family":"Aird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermira","family":"Pazolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Banka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kahlin","family":"Cheung-Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Eifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Furman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua Jeremy","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Seiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Buonamici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Fekkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Karr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4590-7290","authenticated-orcid":false,"given":"James","family":"Palacino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Mizui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Warmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin","family":"Chicas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Corson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,11]]},"reference":[{"key":"8150_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cell.2011.09.016","volume":"147","author":"WR Sellers","year":"2011","unstructured":"Sellers, W. R. A blueprint for advancing genetics-based cancer therapy. Cell 147, 26\u201331 (2011).","journal-title":"Cell"},{"key":"8150_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian, S. L., Taube, J. M., Anders, R. A. & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275\u2013287 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"8150_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nrc.2016.56","volume":"16","author":"AJ Vargas","year":"2016","unstructured":"Vargas, A. J. & Harris, C. C. Biomarker development in the precision medicine era: lung cancer as a case study. Nat. Rev. Cancer 16, 525\u2013537 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"8150_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrclinonc.2016.96","volume":"14","author":"JS Lopez","year":"2017","unstructured":"Lopez, J. S. & Banerji, U. Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat. Rev. Clin. Oncol. 14, 57\u201366 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"8150_CR5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrc.2017.17","volume":"17","author":"P Gotwals","year":"2017","unstructured":"Gotwals, P. et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat. Rev. Cancer 17, 286\u2013301 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"8150_CR6","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin, J. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 371, 1867\u20131876 (2014).","journal-title":"N. Engl. J. Med."},{"key":"8150_CR7","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto, P. A. et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 17, 1248\u20131260 (2016).","journal-title":"Lancet Oncol."},{"key":"8150_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64\u201369 (2011).","journal-title":"Nature"},{"key":"8150_CR9","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/nm.4165","volume":"22","author":"SC Lee","year":"2016","unstructured":"Lee, S. C. & Abdel-Wahab, O. Therapeutic targeting of splicing in cancer. Nat. Med. 22, 976\u2013986 (2016).","journal-title":"Nat. Med."},{"key":"8150_CR10","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.celrep.2018.01.088","volume":"23","author":"M Seiler","year":"2018","unstructured":"Seiler, M. et al. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep. 23, 282\u2013296 e284 (2018).","journal-title":"Cell Rep."},{"key":"8150_CR11","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/nm.4097","volume":"22","author":"SC Lee","year":"2016","unstructured":"Lee, S. C. et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat. Med. 22, 672\u2013678 (2016).","journal-title":"Nat. Med."},{"key":"8150_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.gde.2017.10.010","volume":"48","author":"AA Agrawal","year":"2017","unstructured":"Agrawal, A. A., Yu, L., Smith, P. G. & Buonamici, S. Targeting splicing abnormalities in cancer. Curr. Opin. Genet. Dev. 48, 67\u201374 (2017).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"8150_CR13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nm.4493","volume":"24","author":"M Seiler","year":"2018","unstructured":"Seiler, M. et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat. Med. 24, 497\u2013504 (2018).","journal-title":"Nat. Med."},{"key":"8150_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature14351","volume":"523","author":"CM Koh","year":"2015","unstructured":"Koh, C. M. et al. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature 523, 96\u2013100 (2015).","journal-title":"Nature"},{"key":"8150_CR15","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature14985","volume":"525","author":"TY Hsu","year":"2015","unstructured":"Hsu, T. Y. et al. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature 525, 384\u2013388 (2015).","journal-title":"Nature"},{"key":"8150_CR16","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1101\/gad.212548.112","volume":"27","author":"CG Hubert","year":"2013","unstructured":"Hubert, C. G. et al. Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A. Genes Dev. 27, 1032\u20131045 (2013).","journal-title":"Genes Dev."},{"key":"8150_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15522","volume":"8","author":"T Teng","year":"2017","unstructured":"Teng, T. et al. Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex. Nat. Commun. 8, 15522 (2017).","journal-title":"Nat. Commun."},{"key":"8150_CR18","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nchembio.2007.16","volume":"3","author":"Y Kotake","year":"2007","unstructured":"Kotake, Y. et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat. Chem. Biol. 3, 570\u2013575 (2007).","journal-title":"Nat. Chem. Biol."},{"key":"8150_CR19","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1021\/cb300602j","volume":"8","author":"Y Gao","year":"2013","unstructured":"Gao, Y. & Koide, K. Chemical perturbation of Mcl-1 pre-mRNA splicing to induce apoptosis in cancer cells. ACS Chem. Biol. 8, 895\u2013900 (2013).","journal-title":"ACS Chem. Biol."},{"key":"8150_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/leu.2015.286","volume":"30","author":"M Larrayoz","year":"2016","unstructured":"Larrayoz, M. et al. The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1. Leukemia 30, 351\u2013360 (2016).","journal-title":"Leukemia"},{"key":"8150_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/srep06098","volume":"4","author":"Y Gao","year":"2014","unstructured":"Gao, Y., Trivedi, S., Ferris, R. L. & Koide, K. Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells. Sci. Rep. 4, 6098 (2014).","journal-title":"Sci. Rep."},{"key":"8150_CR22","doi-asserted-by":"publisher","first-page":"4870","DOI":"10.1111\/j.1742-4658.2011.08387.x","volume":"278","author":"A Yokoi","year":"2011","unstructured":"Yokoi, A. et al. Biological validation that SF3b is a target of the antitumor macrolide pladienolide. FEBS J. 278, 4870\u20134880 (2011).","journal-title":"FEBS J."},{"key":"8150_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1021\/cb100248e","volume":"6","author":"M Hasegawa","year":"2011","unstructured":"Hasegawa, M. et al. Identification of SAP155 as the target of GEX1A (Herboxidiene), an antitumor natural product. ACS Chem. Biol. 6, 229\u2013233 (2011).","journal-title":"ACS Chem. Biol."},{"key":"8150_CR24","doi-asserted-by":"publisher","first-page":"11329","DOI":"10.1073\/pnas.0604616103","volume":"103","author":"T Fukuhara","year":"2006","unstructured":"Fukuhara, T. et al. Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc. Natl. Acad. Sci. USA 103, 11329\u201311333 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"8150_CR25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nchembio.2363","volume":"13","author":"T Uehara","year":"2017","unstructured":"Uehara, T. et al. Selective degradation of splicing factor CAPERalpha by anticancer sulfonamides. Nat. Chem. Biol. 13, 675\u2013680 (2017).","journal-title":"Nat. Chem. Biol."},{"key":"8150_CR26","doi-asserted-by":"publisher","unstructured":"Han, T. et al. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science https:\/\/doi.org\/10.1126\/science.aal3755 (2017).","DOI":"10.1126\/science.aal3755"},{"key":"8150_CR27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/01926230701320337","volume":"35","author":"S Elmore","year":"2007","unstructured":"Elmore, S. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35, 495\u2013516 (2007).","journal-title":"Toxicol. Pathol."},{"key":"8150_CR28","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nrc2663","volume":"9","author":"TG Cotter","year":"2009","unstructured":"Cotter, T. G. Apoptosis and cancer: the genesis of a research field. Nat. Rev. Cancer 9, 501\u2013507 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"8150_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrm2308","volume":"9","author":"RJ Youle","year":"2008","unstructured":"Youle, R. J. & Strasser, A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47\u201359 (2008).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"8150_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrc.2015.17","volume":"16","author":"AR Delbridge","year":"2016","unstructured":"Delbridge, A. R., Grabow, S., Strasser, A. & Vaux, D. L. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat. Rev. Cancer 16, 99\u2013109 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"8150_CR31","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1073\/pnas.1205575110","volume":"110","author":"R Haq","year":"2013","unstructured":"Haq, R. et al. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc. Natl. Acad. Sci. USA 110, 4321\u20134326 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"8150_CR32","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/ng.2760","volume":"45","author":"TI Zack","year":"2013","unstructured":"Zack, T. I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134\u20131140 (2013).","journal-title":"Nat. Genet."},{"key":"8150_CR33","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccr.2012.02.028","volume":"21","author":"G Wei","year":"2012","unstructured":"Wei, G. et al. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell. 21, 547\u2013562 (2012).","journal-title":"Cancer Cell."},{"key":"8150_CR34","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421\u20133428 (2008).","journal-title":"Cancer Res."},{"key":"8150_CR35","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1021\/ml5001867","volume":"5","author":"ZF Tao","year":"2014","unstructured":"Tao, Z. F. et al. Discovery of a potent and selective BCL-XL inhibitor with in vivo activity. ACS Med. Chem. Lett. 5, 1088\u20131093 (2014).","journal-title":"ACS Med. Chem. Lett."},{"key":"8150_CR36","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202\u2013208 (2013).","journal-title":"Nat. Med."},{"key":"8150_CR37","doi-asserted-by":"publisher","first-page":"463786","DOI":"10.1155\/2013\/463786","volume":"2013","author":"M Ladomery","year":"2013","unstructured":"Ladomery, M. Aberrant alternative splicing is another hallmark of cancer. Int. J. Cell Biol. 2013, 463786 (2013).","journal-title":"Int. J. Cell Biol."},{"key":"8150_CR38","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1158\/1078-0432.CCR-14-1108","volume":"21","author":"Y Yamamoto","year":"2015","unstructured":"Yamamoto, Y. et al. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth. Clin. Cancer Res. 21, 1675\u20131687 (2015).","journal-title":"Clin. Cancer Res."},{"key":"8150_CR39","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CCO.0000000000000127","volume":"26","author":"D Castanotto","year":"2014","unstructured":"Castanotto, D. & Stein, C. A. Antisense oligonucleotides in cancer. Curr. Opin. Oncol. 26, 584\u2013589 (2014).","journal-title":"Curr. Opin. Oncol."},{"key":"8150_CR40","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.celrep.2012.03.013","volume":"1","author":"M Amit","year":"2012","unstructured":"Amit, M. et al. Differential GC content between exons and introns establishes distinct strategies of splice-site recognition. Cell Rep. 1, 543\u2013556 (2012).","journal-title":"Cell Rep."},{"key":"8150_CR41","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"8150_CR42","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrd.2016.253","volume":"16","author":"A Ashkenazi","year":"2017","unstructured":"Ashkenazi, A., Fairbrother, W. J., Leverson, J. D. & Souers, A. J. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat. Rev. Drug Discov. 16, 273\u2013284 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"8150_CR43","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1158\/1535-7163.MCT-16-0031","volume":"15","author":"A Eastman","year":"2016","unstructured":"R, S. S., Eastman, A. BCL2 inhibitors as anticancer drugs: a plethora of misleading BH3 mimetics. Mol. Cancer Ther. 15, 2011\u20132017 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"8150_CR44","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.cell.2017.07.005","volume":"170","author":"ER McDonald 3rd","year":"2017","unstructured":"McDonald, E. R. 3rd et al. Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening. Cell 170, 577\u2013592 e510 (2017).","journal-title":"Cell"},{"key":"8150_CR45","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564\u2013576 e516 (2017).","journal-title":"Cell"},{"key":"8150_CR46","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nbt.3834","volume":"35","author":"K Han","year":"2017","unstructured":"Han, K. et al. Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. Nat. Biotechnol. 35, 463\u2013474 (2017).","journal-title":"Nat. Biotechnol."},{"key":"8150_CR47","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/j.bmcl.2016.03.032","volume":"26","author":"EJ Hennessy","year":"2016","unstructured":"Hennessy, E. J. Selective inhibitors of Bcl-2 and Bcl-xL: balancing antitumor activity with on-target toxicity. Bioorg. Med. Chem. Lett. 26, 2105\u20132114 (2016).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"8150_CR48","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","volume":"11","author":"WH Wilson","year":"2010","unstructured":"Wilson, W. H. et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 11, 1149\u20131159 (2010).","journal-title":"Lancet Oncol."},{"key":"8150_CR49","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.celrep.2015.09.053","volume":"13","author":"RB Darman","year":"2015","unstructured":"Darman, R. B. et al. Cancer-associated SF3B1 hotspot mutations induce cryptic 3\u2019 splice site selection through use of a different branch point. Cell Rep. 13, 1033\u20131045 (2015).","journal-title":"Cell Rep."},{"key":"8150_CR50","doi-asserted-by":"publisher","first-page":"498","DOI":"10.4161\/cc.8.3.7701","volume":"8","author":"D Wiederschain","year":"2009","unstructured":"Wiederschain, D. et al. Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle 8, 498\u2013504 (2009).","journal-title":"Cell Cycle"},{"key":"8150_CR51","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1073\/pnas.1019736108","volume":"108","author":"KL Meerbrey","year":"2011","unstructured":"Meerbrey, K. L. et al. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc. Natl. Acad. Sci. USA 108, 3665\u20133670 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-08150-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-08150-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-08150-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T14:00:04Z","timestamp":1671199204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-08150-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,11]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["8150"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-08150-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,11]]},"assertion":[{"value":"10 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are present or past employees of H3 Biomedicine, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}